ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email!
Cell Therapy - Technologies, Markets and Companies Published on September 2011
Report Summary This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices. Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues. Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations. The cell-based markets was analyzed for 2010, and projected to 2020.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets. The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 281 of these are profiled in part II of the report along with tabulation of 268 alliances. Of these companies, 160 are involved in stem cells. Profiles of 68 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 51 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.
Table of Content TABLE OF CONTENTS 0. Executive Summary 23 1. Introduction to Cell Therapy 27
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 1/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Introduction 27 Historical landmarks of cell therapy 27 Interrelationship of cell therapy technologies 29 Cells and organ transplantation 29 Cells and protein/gene therapy 30 Cell therapy and regenerative medicine 31 Cells therapy and tissue engineering 31 Therapy based on cells involved in disease 32 Advantages of therapeutic use of cells 32 Cell-based drug delivery 33 Cells as vehicles for gene delivery 33 Red blood cells as vehicles for drug delivery 33 Advantages of cell-based drug delivery 33 Limitations of cell-based drug delivery 34 2. Cell Therapy Technologies 35 Introduction 35 Cell types used for therapy 35 Sources of cells 35 Xenografts 36 Cell lines 36 Immortalized cells 36 Blood component therapy 36 Therapeutic apheresis 36 Leukoreduction 37 Platelet therapy 37 Basic technologies for cell therapy 38 Cell culture 38 Observation of stem cell growth and viability 38 Companies involved in cell culture 39 Cell sorting 40 Flow cytometry 40 A dielectrophoretic system for cell separation 41 Adult stem cell sorting by identification of surface markers 41 ALDESORTER system for isolation of stem cells 42 Dynabead technology for cell sorting 42 Molecular beacons for specific detection and isolation of stem cells 42 Multitarget magnetic activated cell sorter 43 Nanocytometry 43 Scepter' cytometer 43 Companies supplying cell sorters 43 Cell analysis 45 Cell analyzers 45 In vivo cell imaging 45 Measuring cell density 45 Single-cell gene expression analysis 46 Preservation of cells 47 Innovations in cryopreservation 47 Packaging of cells 47
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 2/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Selective expansion of T cells for immunotherapy 48 Cloning and cell therapy 48 Techniques for cell manipulation 49 Cell-based drug discovery 49 Advantages and limitations of cell-based assays for drug discovery 49 Advantages and limitations of cell-based toxicity screening 50 Quality control of cells for drug discovery 50 Companies involved in cell-based drug discovery 50 Drug delivery systems for cell therapy 52 Intravenous delivery of stem cells 53 Pharmacologically active microcarriers 53 Devices for delivery of cell therapy 53 Artificial cells 54 Applications of artificial cells 55 Cell encapsulation 55 Diffusion capsule for cells 55 Encapsulated cell biodelivery 56 Therapeutic applications of encapsulated cells 56 Nitric oxide delivery by encapsulated cells 57 Implantation of microencapulated genetically modified cells 58 Ferrofluid microcapsules for tracking with MRI 58 Companies involved in encapsulated cell technology 59 Electroporation 59 Gene therapy 60 Cell-mediated gene therapy 60 Fibroblasts 60 Chondrocyte 61 Skeletal muscle cells 62 Vascular smooth muscle cells 62 Keratinocytes 62 Hepatocytes 63 Lymphocytes 63 Mammalian artificial chromosomes 63 In vivo tracking of cells 63 Molecular imaging for tracking cells 64 MRI technologies for tracking cells 64 Superparamagnetic iron oxide nanoparticles as MRI contrast agents 65 Visualization of gene expression in vivo by MRI 65 Role of nanobiotechnology in development of cell therapy 66 Cell transplantation for development of organs 66 Cells transplantation and tolerance 67 Strategies to improve tolerance of transplanted cells 67 Encapsulation to prevent immune rejection 67 Prevention of rejection of xenotransplants 68 Expansion of allospecific regulatory T cells 68 Removal and replacement of pathogenic cells of the body 68 Therapeutic leukocytapheresis 68 3. Stem Cells 71
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 3/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Introduction 71 Biology of stem cells 72 Embryonic stem cells 72 Growth and differentiation of ESCs 72 Mechanisms of differentiation of ESCs 73 Chemical regulation of stem cell differentiation 73 In vitro differentiation of hESCs 73 SIRT1 regulation during stem cell differentiation 73 Regulation of stem cell self-renewal and differentiation 74 hESCs for reprogramming human somatic nuclei 74 Stem cells differentiation in the pituitary gland 74 Influence of microenvironment on ESCs 75 Role of genes in differentiation of ESCs 75 Global transcription in pluripotent ESCs 75 Role of p53 tumor suppressor gene in stem cell differentiation 76 Role of Pax3 gene in stem cell differentiation 76 Signaling pathways and ESC genes 76 Epigenetics of hESCs 77 Chromatin as gene regulator for ESC development 77 Comparison of development of human and mouse ESCs 78 Mechanism of regulation of stem cells for regeneration of body tissues 78 Role of microenvironments in the regulation of stem cells 79 Regulation and regeneration of intestinal stem cells 79 Parthenogenesis and human stem cells 79 Uniparental ESCs 80 Bone marrow stem cells 81 Hematopoietic stem cells 81 Role of HSCs in the immune system 83 Derivation of HSCs from ESCs 83 Mesenchymal stem cells 83 Multipotent adult progenitor cells 85 Side population (SP) stem cells 85 Differentiation of adult stem cells 86 Growth and differentiation of HSCs 87 Signaling pathways in the growth and differentiation of HSCs 87 Mathematical modeling of differentiation of HSCs 87 Role of prions in self renewal of HSCs 88 Sources of stem cells 88 Sources of of human embryonic stem cells 88 Nuclear transfer to obtain hESCs 88 Direct derivation of hESCs from embryos without nuclear transfer 89 Alternative methods of obtaining hESCs 90 Establishing hESC lines without destruction of embryo 90 Altered nuclear transfer 91 Small embryonic-like stem cells 91 Advantages and disadvantages of ESCs for transplantation 91 Use of ESC cultures as an alternative source of tissue for transplantation 92 Spermatogonial stem cells 93
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 4/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Amniotic fluid as a source of stem cells 94 Amniotic fluid stem cells for tissue repair and regeneration 94 Generation of iPS cells from AF cells 94 Placenta as source of stem cells 95 Amnion-derived multipotent progenitor cells 95 Placenta as a source of HSCs 96 Umbilical cord as a source of MSCs 96 Umbilical cord blood as source of neonatal stem cells 96 Cryopreservation of UCB stem cells 97 UCB as source of MSCs 97 Applications of UCB 98 Advantages of UCB 98 Limitations of the use of UCB 99 Licensing and patent disputes involving UCB 100 Infections following UCB transplants 100 Unanswered questions about UCB transplantation 101 Companies involved in UCB banking 101 UCB banking in the UK 102 US national UCB banking system 103 Future prospects of UCB as a source of stem cells 104 Induced pluripotent stem cells derived from human somatic cells 104 Characteristics of iPSCs 105 DNA methylation patterns of iPS cells 105 iPSCs derived from skin 105 iPSCs derived from blood 106 Use of retroviral vectors for generation of iPSCs 107 Use of non-integrating viral vectors for generation of iPSCs 107 Clinical relevance of iPSCs 108 Generation of RBCs from iPSCs 108 iPSCs and disease modeling 109 iPSCs for patient-specific regenerative medicine 109 Induced conditional self-renewing progenitor cells 110 Sources of adult human stem cells 110 Adipose tissue as a source of stem cells 111 Intravenous infusion of adipose tissue derived MSCs 111 iPSCs derived from adult human adipose stem cells 111 Regulation of adipose stem cells differentiation 112 Transforming adult adipose stem cells into other cells 112 Multipotent stem-like cells derived from vascular endothelial cells 112 Skin as a source of stem cells 112 Controlling the maturation of embryonic skin stem cells 113 Epidermal neural crest stem cells 113 Follicle stem cells 113 Mesenchymal stem cells in skin 114 Regulation of stem cells in hair follicles 114 Skin-derived precursor cells 115 Stem cells in teeth 115 Peripheral blood stem cells 115
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 5/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Spleen as a source of adult stem cells 116 Search for master stem cells 116 Vascular cell platform to self-renew adult HSC 117 Adult stem cells vs embryonic stem cells 117 Biological differences between adult and embryonic stem cells 117 Neural crest stem cells from adult hair follicles 118 Transdifferentiation potential of adult stem cells 118 Limitations of adult stem cells 119 Comparison of human stem cells according to derivation 120 VENT cells 120 Stem cell banking 120 Stem cell technologies 121 Analysis of stem cell growth and differentiation 121 Tracking self-renewal and expansion of transplanted muscle stem cells 121 Stem cell biomarkers 121 Endoglin as a functional biomarker of HSCs 122 STEMPRO' EZChek' for analysis of biomarkers of hESCs 122 SSEA-4 as biomarker of MSCs 122 p75NTR as a biomarker to isolate adipose tissue-derived stem cells 123 Neural stem cell biomarker 123 Protein expression profile as biomarker of stem cells 123 Real-time PCR for quantification of protein biomarkers 123 Study of stem cell pathways 124 Study of stem cell genes 124 Gene inactivation to study hESCs 125 RNAi to study gene inactivation in hESCs 125 Study of ESC development by inducible RNAi 126 Targeting Induced Local Lesions in Genomes 126 Homologous recombination of ESCs 126 Immortalization of hESCs by telomerase 127 Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease 127 miRNA and stem cells 127 Role of miRNAs in gene regulation during stem cell differentiation 128 Influence of miRNA on stem cell formation and maintenance 128 Transcriptional regulators of ESCs control miRNA gene expression 129 Stem cells and cloning 129 Cell nuclear replacement and cloning 129 Nuclear transfer and ESCs 129 Cloning from differentiated cells 131 Cloning mice from adult stem cells 131 Creating interspecies stem cells 132 Cloned cells for transplantation medicine 132 Claims of cloning of hESCs 132 Cytogenetics of embryonic stem cells 134 Engraftment, mobilization and expansion of stem cells 134 Adipogenesis induced by adipose tissue-derived stem cells 135 Antisense approach for preservation and expansion of stem cells 135 Biomatrials for ESC growth 136
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 6/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Chemoattraction of neuronal stem cells through GABA receptor 136 Enhancement of HSC engraftment by calcium-sensing receptor 137 Enhancement of stem cell differentiation by Homspera 137 Ex vivo expansion of human HSCs in culture 137 Ex vivo expansion of MSCs 138 Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase 138 Expansion of adult stem cells by activation of Oct4 139 Expansion of transduced HSCs in vivo 139 Mobilization of HSCs by growth factors 139 Mobilization of stem cells by cytokines/chemokines 140 Mobilization of adult human HSCs by use of inhibitors 141 Mobilization of stem cells by HYC750 141 Mobilization of stem cells by hyperbaric oxygen 141 Mobilization by adenoviral vectors expressing angiogenic factors 142 Selective mobilization of progenitor cells from bone marrow 142 Selective Amplification 143 Stem cell mobilization by acetylcholine receptor agonists 143 Use of parathyroid hormone to increase HSC mobilzation 143 Expansion of stem cells in vivo by Notch receptor ligands 143 Technologies for inducing differentiation of stem cells 144 Use of lineage selection to induce differentiation of hESCs 144 Growth factor-induced differentiation of MAPCs 144 Neurotrophin-mediated survival and differentiation of hESCs 144 Generation of RBCs from hematopoietic stem cells 145 Generation of multiple types of WBCs from hESCs and iPSCs 145 Use of RNAi to expand the plasticity of autologous adult stem cells 145 Use of carbohydrate molecules to induce differentiation of stem cells 146 Mechanical strain to induce MSC differentiation 146 Limitations of the currently available stem cell lines in the US 146 Contaminating material in stem cell culture and measures to eliminate it 147 Stem cell separation 148 Stem cell culture 149 Culture of hMSCs 149 Long-term maintenance of MSC multipotency in culture 149 Nanofiber scaffolds for stem cell culture 149 Conversion of stem cells to functioning adipocytes 150 Mass production of ESCs 150 Promoting survival of dissociated hESCs 151 Analysis and characterization of stem cells 151 Havesting and identification of EPCs 151 Labeling of stem cells 152 Labeling, imaging and tracking of stem cells in vivo 152 Perfluorocarbon nanoparticles to track therapeutic cells in vivo 152 Project for imaging in stem cell therapy research 152 Quantum dots for labeling and imaging of stem cells 153 Superparamagnetic iron oxide nanoparticles for tracking MSCs 153 Applications of stem cells 154 Commercial development and applications of adult stem cells 154
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 7/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Retrodifferentiation of stem cells 154 MultiStem 155 Controlling the maintenance process of hematopoietic stem cells 155 Self renewal and proliferation of HSCs 155 Aging and rejuvenation of HSCs 155 Peripheral blood stem cell transplantation 156 Role of stem cells in regeneration 156 Promotion of regeneration by Wnt/beta-catenin signaling 156 Stem cells and human reproduction 157 Expansion of spermatogonial stem cells 157 Conversion of ESCs into spermatogonial stem cells 157 Conversion of stem cells to oocytes 158 ESCs for treatment of infertility in women 158 Cloning human embryos from oocytes matured in the laboratory 159 In utero stem cell transplantation 159 Innovations in delivery of stem cells 160 Polymeric capsules for stem cell delivery 160 Immunological aspects of hESC transplantation 161 Immunosuppression to prevent rejection of hESC transplants 161 Histocompatibility of hESCs 161 Strategies for promoting immune tolerance of hESCs 162 Stem cells for organ vascularization 162 Activation of EphB4 to enhance angiogenesis by EPCs 163 Advantages and limitations of clinical applications of MSCs 163 Biofusion by genetically engineering stem cells 164 Stem cell gene therapy 164 Combination of gene therapy with nuclear transfer 164 Gene delivery to stem cells by artificial chromosome expression 165 Genetic manipulation of ESCs 165 Genetic engineering of human stem cells for enhancing angiogenesis 165 HSCs for gene therapy 166 Helper-dependent adenoviral vectors for gene transfer in ESCs 166 Lentiviral vectors for in vivo gene transfer to stem cells 167 Linker based sperm-mediated gene transfer technology 167 Mesenchymal stem cells for gene therapy 167 Microporation for transfection of MSCs 167 Regulation of gene expression for SC-based gene therapy 168 Stem cells and in utero gene therapy 168 Therapeutic applications for hematopoietic stem cell gene transfer 169 The future of hematopoietic stem cell gene therapy 169 Stem cell pharmaceutics 169 Cardiomyocytes derived from hESCs 169 ESCs as source of models for drug discovery 170 hESC-derived hepatocytes for drug discovery 171 Pharmaceutical manipulation of stem cells 171 Role of stem cells in therapeutic effects of drugs 173 Stem cells for drug discovery 173 Stem cells for drug delivery 174
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 8/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Stem cell activation for regeneration by using glucocortoids 174 Toxicology and drug safety studies using ESCs versus other cells 175 Future challenges for stem cell technologies 177 Study of the molecular mechanism of cell differentiation 177 MBD3-deficient ESC line 177 In vivo study of human hemopoietic stem cells 178 Stem cell biology and cancer 178 Research into plasticity of stem cells from adults 179 Stem cells and aging 179 Activation of bone marrow stem cells into therapeutic cells 180 Role of nitric oxide in stem cell mobilization and differentiation 180 Stem cell genes 181 Gene expression in hESCs 181 The casanova gene in zebrafish 182 Nanog gene 182 Stem cell proteomics 183 hESC phosphoproteome 183 Proteomic studies of mesenchymal stem cells 184 Proteomic profiling of neural stem cells 184 Proteome Biology of Stem Cells Initiative 185 Genomic alterations in cultured hESCs 185 Hybrid embryos/cybrids for stem cell research 185 Generation of patient-specific pluripotent stem cells 186 Markers for characterizing hESC lines 187 Switch of stem-cell function from activators to repressors 187 Stem cell research at academic centers 187 International Regulome Consortium 189 Companies involved in stem cell technologies 189 Concluding remarks about stem cells 194 Challenges and future prospects of stem cell research 194 4. Clinical Applications of Cell Therapy 197 Introduction 197 Cell therapy for hematological disorders 197 Transplantation of autologous hematopoietic stem cells 197 Hemophilias 197 Ex vivo cell/gene therapy of hemophilia B 197 Cell/gene therapy of hemophilia A 198 Hematopoietic stem cell therapy for thrombocytopenia 199 Stem cell transplant for sickle cell anemia 199 Treatment of chronic acquired anemias 200 Implantation of genetically engineered HSCs to deliver rhEpo 200 Drugs acting on stem cells for treatment of anemia 200 Stem cell therapy of hemoglobinopathies 201 Stem cells for treatment of immunoglobulin-light chain amyloidosis 201 Future prospects of cell therapy of hematological disorders 201 Cell therapy for immunological disorders 202 Role of dendritic cells in the immune system 202 Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures 202
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 9/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Stem cell therapy of chronic granulomatous disease 203 Stem cell therapy of X-linked severe combined immunodeficiency 203 Stem cell therapy of autoimmune disorders 204 Treatment of rheumatoid arthritis with stem cells 204 Treatment of Crohn's disease with stem cells 204 Stem cell transplants for scleroderma 205 Role of T Cells in immunological disorders 205 Autologous T cells from adult stem cells 206 Cell therapy for graft vs host disease 207 MSCs for GVHD 207 Cell therapy for viral infections 208 T-cell therapy for CMV 208 T-cell therapy for HIV infection 208 T-cell immunity by Overlapping Peptide-pulsed Autologous Cells 209 Anti-HIV ribozyme delivered in hematopoietic progenitor cells 209 Dendritic-cell targeted DNA vaccine for HIV 210 Cell therapy of lysosomal storage diseases 210 Niemann-Pick disease 210 Gaucher's disease 211 Fabry's disease 211 Cell therapy for diabetes mellitus 212 Limitations of current treatment 213 Limitations of insulin therapy for diabetes mellitus 213 Limitations of pancreatic transplantation 213 Islet cell transplantation 213 Autologous pancreatic islet cell transplantation in chronic pancreatitis 214 Clinical trials of pancreatic islet cell transplants for diabetes 214 Drawbacks of islet cell therapy 215 Use of an antioxidant peptide to improve islet cell transplantation 215 Cdk-6 and cyclin D1 enhance human beta cell replication and function 216 A device for delivery of therapeutic cells in diabetes 216 Monitoring of islet cell transplants with MRI 216 Concluding remarks about allogeneic islet transplantation for diabetes 216 Encapsulation of insulin producing cells 217 Encapsulated porcine pancreatic islet cells for pancreas 217 Encapsulated insulinoma cells 217 Magnetocapsule enables imaging/tracking of islet cell transplants 218 Islet precursor cells 218 Dedifferentiation of ' cells to promote regeneration 219 Pharmacological approaches for ' cell regeneration 219 Xenotransplantation of embryonic pancreatic tissue 220 Non-pancreatic tissues for generation of insulin-producing cells 220 Exploiting maternal microchimerism to treat diabetes in the child 220 Bio-artificial substitutes for pancreas 221 Role of stem cells in the treatment of diabetes 221 Embryonic stem cells for diabetes 221 HSC transplantation to supplement immunosuppressant therapy 223 Human neural progenitor cells converted into insulin-producing cells 223
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 10/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Insulin-producing cells derived from UCB stem cells 223 iPS cells for diabetes 224 Isolation of islet progenitor cells 224 Pancreatic progenitor cells Expansion in vitro 224 Pancreatic stem cells 225 Stem cell injection into portal vein of diabetic patients 225 Dendritic cell-based therapy for type 1 diabetes 226 Vaccine for diabetes 226 Gene therapy in diabetes 226 Viral vectors for gene therapy of diabetes 226 Genetically engineered dendritic cells 227 Genetically altered liver cells 227 Genetically modified stem cells 227 Companies developing cell therapy for diabetes 228 Concluding remarks about cell and gene therapy of diabetes 229 Cell therapy of gastrointestinal disorders 230 Inflammatory bowel disease 230 Cell therapy for liver disorders 230 Types of cells and methods of delivery for hepatic disorders 231 Bioartificial liver 232 Limitations of bioartificial liver 232 Stem cells for hepatic disorders 233 Deriving hepatocytes from commercially available hMSCs 234 Implantation of hepatic cells derived from hMSCs of adipose tissue 234 MSC derived molecules for reversing hepatic failure 234 Cell-based gene therapy for liver disorders 235 Transplantation of genetically modified fibroblasts 235 Transplantation of genetically modified hepatocytes 235 Intraperitoneal hepatocyte transplantation 235 Genetically modified hematopoietic stem cells 236 Use of iPSCs derived from somatic cells for liver regeneration 236 Clinical applications 236 Future prospects of cell-based therapy of hepatic disorders 237 Cell therapy of renal disorders 237 Bioartificial kidney 237 Cell-based repair for vascular access failure in renal disease 238 Mesangial cell therapy for glomerular disease 238 Stem cells for renal disease 238 Role of stem cells in renal repair 239 Bone marrow stem cells for renal disease 239 MSC therapy for renal disease 240 Cell therapy for pulmonary disorders 240 Delivery of cell therapy for pumonary disorders 240 Intratracheal injection of cells for pulmonary hypoplasia 240 Role of stem cells in pulmonary disorders 240 Lung stem cells 240 Lung tissue regeneration from stem cells 241 Role of stem cells in construction of the Cyberlung 241
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 11/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Respiratory epithelial cells derived from UCB stem cells 242 Respiratory epithelial cells derived from hESCs 242 Lung tissue engineering with adipose stromal cells 242 Cell-based tissue-engineering of airway 243 Pulmonary disorders that can be treatable with stem cells 243 Acute lung injury and ARDS treated with MSCs 244 Bronchopulmonary dysplasia treated with MSCs 245 Chronic obstructive pulmonary disease treated with MSCs 245 Cystic fibrosis treatment with genetically engineered MSCs 245 Lung regeneration by integrin '6'4-expressing alveolar epithelial cell 245 Pulmonary arterial hypertension treatment with EPCs 246 Cell therapy for disorders of bones and joints 246 Repair of fractures and bone defects 247 Adult stem cells for bone grafting 247 Cell therapy for osteonecrosis 248 Cell therapy for cervical vertebral interbody fusion 248 ESCs for bone repair 248 Intrauterine use of MSCs for osteogenesis imperfecta 249 In vivo bone engineering as an alternative to cell transplantation 249 MSCs for repair of bone defects 249 MSCs for repair of bone fractures 252 Osteocel 252 Stem cells for repairing skull defects 253 Stem cell-based bone tissue engineering 253 Spinal fusion using stem cell-based bone grafts 254 Osteoarthritis and other injuries to the joints 254 Mosaicplasty 255 Autologous cultured chondrocytes 255 Autologous intervertebral disc chondrocyte transplantation 256 Cartilage repair by genetically modified fibroblasts expressing TGF-' 257 Generation of cartilage from stem cells 257 Role of cell therapy in repair of knee cartilage injuries 259 Role of cells in the repair of anterior cruciate ligament injury 261 Autologous tenocyte implantation in rotator cuff injury repair 261 Platelet injection for tennis elbow 262 Cell therapy of rheumatoid arthritis 262 Cell therapy for diseases of the eye 263 Cell therapy for corneal repair 263 Stem cell therapy for limbal stem cell deficiency 264 Role of stem cells in fibrosis following eye injury 265 Stem cell transplantation for radiation sickness 265 MSCs for treatment of radiation damage to the bone 265 MSCs for regeneration of ovaries following radiotherapy damage 266 Cell therapy for regeneration 266 Stem cells for regenerating organs 266 Umbilical cord blood for regeneration 267 Role of stem cells in regeneration of esophageal epithelium 267 Cell therapy for regeneration of muscle wasting 267
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 12/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Wound healing: skin and soft tissue repair 268 Cells to form skin substitutes for healing ulcers 269 CellSpray for wound repair 269 Cell therapy for burns 270 Closure of incisions with laser guns and cells 271 Follicular stem cells for skin and wound repair 271 Reprogramming autologous stem cells for wound regeneration 272 Role of amniotic fluid MSCs in repair of fetal wounds 272 Genetically engineered keratinocytes for wound repair 272 MSCs for wound healing 272 Regeneration of aging skin by adipose-derived stem cells 273 Repair of aging skin by injecting autologous fibroblasts 273 Role of cells in tissue engineering and reconstructive surgery 273 Stem cells for tissue repair 273 Scaffolds for tissue engineering 274 Improving vascularization of engineered tissues 274 Enhancing vascularization by combining cell and gene therapy 275 Choosing cells for tissue engineering 275 ESCs vs adult SCs for tissue engineering 275 Use of adult MSCs for tissue engineering 276 Nanobiotechnology applied to cells for tissue engineering 276 Stem cells for tissue engineering of various organs 277 Engineering of healthy living teeth from stem cells 277 Adipose tissue-derived stem cells for breast reconstruction 278 Improving tissue engineering of bone by MSCs 278 Intra-uterine repair of congenital defects using amniotic fluid MSCs 279 Cell-based tissue engineering in genitourinary system 279 Urinary incontinence 279 Tissue engineering of urinary bladder 281 Label retaining urothelial cells for bladder repair 281 MSCs for bladder repair 281 Tissue-engineering of urethra using autologous cells 282 Repair of the pelvic floor with stem cells from the uterus 282 Reconstruction of vagina from stem cells 282 Facial skin regeneration by stem cells as an alternative to face transplant 283 Cell therapy for rejuvenation 283 Cell therapy for performance enhancement in sports 283 Application of stem cells in veterinary medicine 284 Use of stem cells to repair tendon injuries 284 Stem cells for spinal cord injury in dogs 284 5. Cell Therapy for Cardiovascular Disorders 287 Introduction to cardiovascular disorders 287 Limitations of current therapies for myocardial ischemic disease 287 Types of cell therapy for cardiovascular disorders 287 Cell-mediated immune modulation for chronic heart disease 288 Human cardiovascular progenitor cells 289 Inducing the proliferation of cardiomyocytes 289 Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia 290
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 13/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Role of splenic myocytes in repair of the injured heart 290 Reprogramming of fibroblasts into functional cardiomyocytes 290 Small molecules to enhance myocardial repair by stem cells 291 Cell therapy for atherosclerotic coronary artery disease 291 MyoCell' (Bioheart) 292 Cardiac stem cells 292 Cardiomyocytes derived from epicardium 293 Methods of delivery of cells to the heart 293 Cellular cardiomyoplasty 294 IGF-1 delivery by nanofibers to improve cell therapy for MI 294 Non-invasive delivery of cells to the heart by Morph速guide catheter 294 Cell therapy for cardiac revascularization 294 Transplantation of cardiac progenitor cells for revascularization of myocardium 294 Stem cells to prevent restenosis after coronary angioplasty 295 Role of cells in cardiac tissue repair 296 Modulation of cardiac macrophages for repair of infarct 296 Transplantation of myoblasts for myocardial infarction 296 Patching myocardial infarction with fibroblast culture 297 Cardiac repair with myoendothelial cells from skeletal muscle 297 Myocardial tissue engineering 297 Role of stem cells in repair of the heart 298 Role of stem cells in cardiac regeneration following injury 298 Cardiomyocytes derived from adult skin cells 299 Cardiomyocytes derived from ESCs 299 Studies to identify subsets of progenitor cells suitable for cardiac repair 300 Technologies for preparation of stem cells for cardiovascular therapy 301 Pravastatin for expansion of endogenous progenitor and stem cells 301 Cytokine preconditioning of human fetal liver CD133+ SCs 301 Expansion of adult cardiac stem cells for transplantation 302 Role of MSCs in growth of CSCs 302 Role of ESCs in repair of the heart 302 ESC transplantation for tumor-free repair of the heart 303 Transplantation of stem cells for myocardial infarction 304 Autologous bone marrow-derived stem cell therapeutics 304 Autologous bone marrow-derived mesenchymal precursor stem cells 304 Transplantation of cord blood stem cells 304 Transplantation of hESCs 305 Transplantation of HSCs 305 Transplantation of autologous angiogenic cell precursors 306 Transplantation of adipose-derived stem cells 306 Transplantation of bone marrow-derived cells for myocardial infarct 307 Intracoronary infusion of mobilized peripheral blood stem cells 308 Transplantation of endothelial cells 308 Transplantation of cardiomyocytes differentiated from hESCs 308 Stem cell therapy for cardiac regeneration 309 Regeneration of the chronic myocardial infarcts by HSC therapy 309 Human mesenchymal stem cells for cardiac regeneration 309 In vivo tracking of MSCs transplanted in the heart 310
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 14/17
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! MSCs for hibernating myocardium 311 Simultaneous transplantation of MSCs and skeletal myoblasts 311 Transplantation of genetically modified cells 311 Transplantation of genetically modified MSCs 311 Transplantation of cells secreting vascular endothelial growth factor 312 Transplantation of genetically modified bone marrow stem cells 312 Cell transplantation for congestive heart failure 312 Myoblasts for treatment of congestive heart failure 313 Injection of adult stem cells for CHF 313 AngioCell gene therapy for congestive heart failure 314 Stem cell therapy for dilated cardiac myopathy 314 Role of cell therapy in cardiac arrhythmias 315 Atrioventricular conduction block 315 Genetically engineered cells as biological pacemakers 316 Ventricular tachycardia 317 Prevention of myoblast-induced arrhythmias by genetic engineering 317 ESCs for correction of congenital heart defects 317 Cardiac progenitors cells for treatment of heart disease 318 Autologus stem cells for chronic myocardial ischemia 318 Role of cells in cardiovascular tissue engineering 319 Construction of blood vessels with cells 319 Engineered arteries for bypass grafts 319 Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts 320 Targeted delivery of endothelial progenitor cells labeled with nano
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 15/17
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ
Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information Please verify that the product information is correct and select the format(s) you require. Cell Therapy - Technologies, Markets and Companies
Product Formats Please select the product formats and the quantity you require.
Digital Copy--USD 5 500.00
Quantity: _____
Contact Information Please enter all the information below in BLOCK CAPITALS
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
First Name:
_____________________________ Last Name: __________________________________
Email Address:
__________________________________________________________________________
Job Title:
__________________________________________________________________________
Organization:
__________________________________________________________________________
Address:
__________________________________________________________________________
City:
__________________________________________________________________________
Postal / Zip Code:
__________________________________________________________________________
Country:
__________________________________________________________________________
Phone Number:
__________________________________________________________________________
Fax Number:
__________________________________________________________________________
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 16/17
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card
Card Number: ______________________________________________
Expiry Date
__________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer
Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check
UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms
Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Cell Therapy - Technologies, Markets and Companies (From Issuu)
Page 17/17